{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:37:45Z","timestamp":1780634265104,"version":"3.54.1"},"reference-count":128,"publisher":"Elsevier","isbn-type":[{"value":"9780443313585","type":"print"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.apha.2024.10.008","type":"book-chapter","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T18:13:57Z","timestamp":1729620837000},"page":"203-236","source":"Crossref","is-referenced-by-count":4,"title":["BRD4 as an emerging epigenetic therapeutic target for inflammatory bowel disease"],"prefix":"10.1016","member":"78","reference":[{"issue":"2","key":"10.1016\/bs.apha.2024.10.008_bib1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/17474124.2019.1553618","article-title":"An update on the evaluation and management of iron deficiency anemia in inflammatory bowel disease","volume":"13","author":"Aksan","year":"2019","journal-title":"Expert Review of Gastroenterology & Hepatology"},{"issue":"14","key":"10.1016\/bs.apha.2024.10.008_bib2","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1128\/MCB.00586-07","article-title":"Differential regulation of NF-kappaB by elongation factors is determined by core promoter type","volume":"27","author":"Amir-Zilberstein","year":"2007","journal-title":"Molecular and Cellular Biology"},{"issue":"4","key":"10.1016\/bs.apha.2024.10.008_bib3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1177\/1756283X16636781","article-title":"Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn\u2019s disease","volume":"9","author":"Ardizzone","year":"2016","journal-title":"Therapeutic Advances in Gastroenterology"},{"issue":"9","key":"10.1016\/bs.apha.2024.10.008_bib4","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1158\/0008-5472.CAN-16-2622","article-title":"Targeted degradation of BET proteins in triple-negative breast cancer","volume":"77","author":"Bai","year":"2017","journal-title":"Cancer Research"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.008_bib5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1097-2765(01)00314-8","article-title":"NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II","volume":"8","author":"Barboric","year":"2001","journal-title":"Molecular Cell"},{"issue":"7","key":"10.1016\/bs.apha.2024.10.008_bib6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrc3256","article-title":"BET domain co-regulators in obesity, inflammation and cancer","volume":"12","author":"Belkina","year":"2012","journal-title":"Nature Reviews. Cancer"},{"issue":"34","key":"10.1016\/bs.apha.2024.10.008_bib7","doi-asserted-by":"crossref","first-page":"13690","DOI":"10.1073\/pnas.0705053104","article-title":"Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription","volume":"104","author":"Bisgrove","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"13_Supplement","key":"10.1016\/bs.apha.2024.10.008_bib8","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1158\/1538-7445.AM2019-4452","article-title":"Abstract 4452: GNE-0011, a novel monovalent BRD4 degrader","volume":"79","author":"Blake","year":"2019","journal-title":"Cancer Research"},{"key":"10.1016\/bs.apha.2024.10.008_bib9","unstructured":"Blake, R. A. P. D., Gaz-Zard, L. J., Kaufman, S., Kleinheinz, T., Pillow, T., et al. (2020). Tert-butyl (S)-2-(4-(phenyl)-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate derivatives and related compounds as bromodomain BRD4 inhibitors for treating cancer. https:\/\/doi.org\/WO2020055976A1."},{"issue":"1","key":"10.1016\/bs.apha.2024.10.008_bib10","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.drudis.2019.11.002","article-title":"Validation of the epigenetic reader bromodomain-containing protein 4 (BRD4) as a therapeutic target for treatment of airway remodeling","volume":"25","author":"Brasier","year":"2020","journal-title":"Drug Discovery Today"},{"issue":"5","key":"10.1016\/bs.apha.2024.10.008_bib11","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S2468-1253(23)00003-1","article-title":"The cost of inflammatory bowel disease in high-income settings: A Lancet Gastroenterology & Hepatology Commission","volume":"8","author":"Burisch","year":"2023","journal-title":"Lancet Gastroenterology & Hepatology"},{"issue":"16","key":"10.1016\/bs.apha.2024.10.008_bib12","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1039\/D2CS00220E","article-title":"Chemistries of bifunctional PROTAC degraders","volume":"51","author":"Cao","year":"2022","journal-title":"Chemical Society Reviews"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.008_bib13","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/1078-0432.CCR-23-0133","article-title":"A phase I\/II study of GSK525762 combined with fulvestrant in patients with hormone receptor-positive\/HER2-negative advanced or metastatic breast cancer","volume":"30","author":"Cescon","year":"2024","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.008_bib14","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1021\/acs.jmedchem.6b01912","article-title":"Impact of target warhead and linkage vector on inducing protein degradation: Comparison of bromodomain and extra-terminal (BET) degraders derived from triazolodiazepine (JQ1) and tetrahydroquinoline (I-BET726) BET inhibitor scaffolds","volume":"61","author":"Chan","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"issue":"7","key":"10.1016\/bs.apha.2024.10.008_bib15","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1021\/acs.jmedchem.1c01835","article-title":"Targeting bromodomain-selective inhibitors of BET proteins in drug discovery and development","volume":"65","author":"Chen","year":"2022","journal-title":"Journal of Medicinal Chemistry"},{"issue":"5","key":"10.1016\/bs.apha.2024.10.008_bib16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1177\/2040622315586970","article-title":"Vedolizumab: An alpha4beta7 integrin antagonist for ulcerative colitis and Crohn\u2019s disease","volume":"6","author":"Cherry","year":"2015","journal-title":"Therapeutic Advances in Chronic Disease"},{"key":"10.1016\/bs.apha.2024.10.008_bib17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic\u2014A new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.1016\/bs.apha.2024.10.008_bib18","doi-asserted-by":"crossref","DOI":"10.1007\/s10620-024-08302-2","article-title":"Upadacitinib as rescue therapy for the treatment of acute severe colitis in an acute care setting","author":"Clinton","year":"2024","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1016\/bs.apha.2024.10.008_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818821266","article-title":"Golimumab in the treatment of ulcerative colitis","volume":"12","author":"Cunningham","year":"2019","journal-title":"Therapeutic Advances in Gastroenterology"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.008_bib20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12876-020-01548-w","article-title":"Recurrence of moderate to severe ulcerative colitis after fecal microbiota transplantation treatment and the efficacy of re-FMT: A case series","volume":"20","author":"Dang","year":"2020","journal-title":"BMC Gastroenterology"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.008_bib21","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1053\/j.gastro.2022.08.038","article-title":"Intestinal ultrasound is accurate to determine endoscopic response and remission in patients with moderate to severe ulcerative colitis: A longitudinal prospective cohort study","volume":"163","author":"de Voogd","year":"2022","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.008_bib22","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nsmb.3228","article-title":"BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin","volume":"23","author":"Devaiah","year":"2016","journal-title":"Nature Structural & Molecular Biology"},{"issue":"26","key":"10.1016\/bs.apha.2024.10.008_bib23","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"The New England Journal of Medicine"},{"issue":"6735","key":"10.1016\/bs.apha.2024.10.008_bib24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/20974","article-title":"Structure and ligand of a histone acetyltransferase bromodomain","volume":"399","author":"Dhalluin","year":"1999","journal-title":"Nature"},{"issue":"51","key":"10.1016\/bs.apha.2024.10.008_bib25","doi-asserted-by":"crossref","first-page":"15713","DOI":"10.1073\/pnas.1522163112","article-title":"BRD4 is a novel therapeutic target for liver fibrosis","volume":"112","author":"Ding","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.008_bib26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","article-title":"BRD4 and cancer: Going beyond transcriptional regulation","volume":"17","author":"Donati","year":"2018","journal-title":"Molecular Cancer"},{"issue":"15","key":"10.1016\/bs.apha.2024.10.008_bib27","doi-asserted-by":"crossref","first-page":"10606","DOI":"10.1021\/acs.jmedchem.1c00895","article-title":"Molecular glues for targeted protein degradation: From serendipity to rational discovery","volume":"64","author":"Dong","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.008_bib28","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.cgh.2019.12.020","article-title":"How do we treat inflammatory bowel diseases to aim for endoscopic remission?","volume":"18","author":"Dulai","year":"2020","journal-title":"Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association"},{"issue":"4","key":"10.1016\/bs.apha.2024.10.008_bib29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2036.2004.02046.x","article-title":"Review article: Colorectal carcinoma and inflammatory bowel disease","volume":"20","author":"Eaden","year":"2004","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"4","key":"10.1016\/bs.apha.2024.10.008_bib30","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/gut.48.4.526","article-title":"The risk of colorectal cancer in ulcerative colitis: A meta-analysis","volume":"48","author":"Eaden","year":"2001","journal-title":"Gut"},{"issue":"16","key":"10.1016\/bs.apha.2024.10.008_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23168905","article-title":"Mesenchymal (stem) stromal cells based as new therapeutic alternative in inflammatory bowel disease: Basic mechanisms, experimental and clinical evidence, and challenges","volume":"23","author":"Eiro","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"Supplement_1","key":"10.1016\/bs.apha.2024.10.008_bib32","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1093\/ecco-jcc\/jjx180.540","article-title":"P413 Relative frequency of relapses in patients with ulcerative colitis and Crohn\u2019s disease treated with mesenchymal stromal cells: Five-years of follow-up","volume":"12","author":"Fadeeva","year":"2018","journal-title":"Journal of Crohn\u2019s and Colitis"},{"issue":"17","key":"10.1016\/bs.apha.2024.10.008_bib33","doi-asserted-by":"crossref","first-page":"11454","DOI":"10.1021\/acs.jmedchem.2c00844","article-title":"Progress and challenges in targeted protein degradation for neurodegenerative disease therapy","volume":"65","author":"Fang","year":"2022","journal-title":"Journal of Medicinal Chemistry"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.008_bib34","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/med.21859","article-title":"Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: A review from medicinal chemistry perspectives","volume":"42","author":"Feng","year":"2022","journal-title":"Medicinal Research Reviews"},{"issue":"12","key":"10.1016\/bs.apha.2024.10.008_bib35","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1038\/s41591-023-02622-y","article-title":"PROTACs reach clinical development in inflammatory skin disease","volume":"29","author":"Ferguson","year":"2023","journal-title":"Nature Medicine"},{"issue":"5","key":"10.1016\/bs.apha.2024.10.008_bib36","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrd4286","article-title":"Targeting bromodomains: Epigenetic readers of lysine acetylation","volume":"13","author":"Filippakopoulos","year":"2014","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.008_bib37","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.cell.2012.02.013","article-title":"Histone recognition and large-scale structural analysis of the human bromodomain family","volume":"149","author":"Filippakopoulos","year":"2012","journal-title":"Cell"},{"issue":"7327","key":"10.1016\/bs.apha.2024.10.008_bib38","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"issue":"10","key":"10.1016\/bs.apha.2024.10.008_bib39","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/14712598.2019.1564033","article-title":"Biosimilars of adalimumab: The upcoming challenge in IBD","volume":"19","author":"Fiorino","year":"2019","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1016\/bs.apha.2024.10.008_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113853","article-title":"Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins","volume":"226","author":"Fu","year":"2021","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"3","key":"10.1016\/bs.apha.2024.10.008_bib41","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/acsmedchemlett.9b00597","article-title":"PROTAC technology: Opportunities and challenges","volume":"11","author":"Gao","year":"2020","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.008_bib42","doi-asserted-by":"crossref","first-page":"10280","DOI":"10.1038\/s41598-019-46516-x","article-title":"Bromodomain inhibitor JQ1 reversibly blocks IFN-gamma production","volume":"9","author":"Gibbons","year":"2019","journal-title":"Scientific Reports"},{"issue":"7973","key":"10.1016\/bs.apha.2024.10.008_bib43","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41586-023-06348-2","article-title":"Rewiring cancer drivers to activate apoptosis","volume":"620","author":"Gourisankar","year":"2023","journal-title":"Nature"},{"issue":"17","key":"10.1016\/bs.apha.2024.10.008_bib44","doi-asserted-by":"crossref","first-page":"13231","DOI":"10.3390\/ijms241713231","article-title":"BRD4 as a therapeutic target in pulmonary diseases","volume":"24","author":"Guo","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.apha.2024.10.008_bib45","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cbpa.2019.11.012","article-title":"Targeted protein degradation: Current and future challenges","volume":"56","author":"Hanzl","year":"2020","journal-title":"Current Opinion in Chemical Biology"},{"issue":"e 2","key":"10.1016\/bs.apha.2024.10.008_bib46","doi-asserted-by":"crossref","first-page":"ii45","DOI":"10.1093\/rheumatology\/keaa896","article-title":"JAK1 inhibition and inflammatory bowel disease","volume":"60","author":"Harris","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.008_bib47","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-022-00999-9","article-title":"PROTACs: Great opportunities for academia and industry (an update from 2020 to 2021)","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"8","key":"10.1016\/bs.apha.2024.10.008_bib48","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40262-017-0627-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of infliximab in the treatment of inflammatory bowel disease","volume":"57","author":"Hemperly","year":"2018","journal-title":"Clinical Pharmacokinetics"},{"issue":"22","key":"10.1016\/bs.apha.2024.10.008_bib49","doi-asserted-by":"crossref","first-page":"9393","DOI":"10.1021\/jm300915b","article-title":"Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions","volume":"55","author":"Hewings","year":"2012","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.apha.2024.10.008_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-024-07089-6","article-title":"Targeted protein degradation via intramolecular bivalent glues","author":"Hsia","year":"2024","journal-title":"Nature"},{"key":"10.1016\/bs.apha.2024.10.008_bib51","unstructured":"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02586155?term=RVX-208&phase=2&draw=2&rank=1. Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD (BETonMACE). [Accessed 29 March 2024]."},{"key":"10.1016\/bs.apha.2024.10.008_bib52","unstructured":"https:\/\/drughunter.com\/the-molecular-glue-degrader-landscape-in-2022. The Molecular Glue Degrader Landscape in 2022. [Accessed 29 March 2024]."},{"key":"10.1016\/bs.apha.2024.10.008_bib53","unstructured":"https:\/\/investors.kymeratx.com\/news-events\/press-releases.R&D Day Highlights Kymera\u2019s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases. [Accessed 29 March 2024]."},{"key":"10.1016\/bs.apha.2024.10.008_bib54","unstructured":"https:\/\/www.kymeratx.com. [Accesseed 29 March 2024]."},{"issue":"5","key":"10.1016\/bs.apha.2024.10.008_bib55","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1128\/MCB.01365-08","article-title":"Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA","volume":"29","author":"Huang","year":"2009","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/bs.apha.2024.10.008_bib56","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.4c00141","article-title":"Peptide inhibitor targeting the extraterminal domain in BRD4 potently suppresses breast cancer both in vitro and in vivo","author":"Huang","year":"2024","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.008_bib57","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/iwj.13076","article-title":"Depression and resilience in ulcerative colitis and Crohn\u2019s disease patients with ostomy","volume":"16","author":"Hwang","year":"2019","journal-title":"International Wound Journal"},{"issue":"12","key":"10.1016\/bs.apha.2024.10.008_bib58","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1093\/nar\/gku449","article-title":"Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation","volume":"42","author":"Itzen","year":"2014","journal-title":"Nucleic Acids Research"},{"issue":"12","key":"10.1016\/bs.apha.2024.10.008_bib59","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1080\/14740338.2023.2236554","article-title":"Safety and efficacy of personalized versus standard initial dosing of thiopurines: Systematic review and meta-analysis of randomized trials","volume":"22","author":"Jena","year":"2023","journal-title":"Expert Opinion on Drug Safety"},{"issue":"10","key":"10.1016\/bs.apha.2024.10.008_bib60","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1038\/s41591-021-01519-y","article-title":"Individualized therapy trials: Navigating patient care, research goals and ethics","volume":"27","author":"Kane","year":"2021","journal-title":"Nature Medicine"},{"issue":"12","key":"10.1016\/bs.apha.2024.10.008_bib61","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: From 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"issue":"4","key":"10.1016\/bs.apha.2024.10.008_bib62","first-page":"495","article-title":"Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: A systematic review","volume":"44","author":"Khan","year":"2019","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.008_bib63","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41575-022-00738-z","article-title":"Improving IBD outcomes in the era of many treatment options","volume":"20","author":"Kobayashi","year":"2023","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"issue":"12","key":"10.1016\/bs.apha.2024.10.008_bib64","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: Past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chemical Society Reviews"},{"key":"10.1016\/bs.apha.2024.10.008_bib65","article-title":"Template-assisted covalent modification of DCAF16 underlies activity of BRD4 molecular glue degraders","author":"Li","year":"2023","journal-title":"bioRxiv"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.008_bib66","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1093\/ibd\/izab190","article-title":"Target-based small molecule drug discovery towards novel therapeutics for inflammatory bowel diseases","volume":"27","author":"Li","year":"2021","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/bs.apha.2024.10.008_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112426","article-title":"Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery","volume":"200","author":"Liang","year":"2020","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.apha.2024.10.008_bib68","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fphar.2019.00039","article-title":"Cellular mechanisms of etrolizumab treatment in inflammatory bowel disease","volume":"10","author":"Lichnog","year":"2019","journal-title":"Frontiers in Pharmacology"},{"issue":"10","key":"10.1016\/bs.apha.2024.10.008_bib69","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.jpedsurg.2019.01.006","article-title":"Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn\u2019s patients","volume":"54","author":"Lightner","year":"2019","journal-title":"Journal of Pediatric Surgery"},{"issue":"10","key":"10.1016\/bs.apha.2024.10.008_bib70","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/s41440-020-0459-4","article-title":"The therapeutic potential of BRD4 in cardiovascular disease","volume":"43","author":"Lin","year":"2020","journal-title":"Hypertension Research: Official Journal of the Japanese Society of Hypertension"},{"issue":"7","key":"10.1016\/bs.apha.2024.10.008_bib71","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1021\/acscentsci.3c00395","article-title":"Proximity-based modalities for biology and medicine","volume":"9","author":"Liu","year":"2023","journal-title":"ACS Central Science"},{"issue":"10","key":"10.1016\/bs.apha.2024.10.008_bib72","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1021\/acs.jmedchem.0c00035","article-title":"Discovery of orally bioavailable chromone derivatives as potent and selective BRD4 inhibitors: Scaffold hopping, optimization, and pharmacological evaluation","volume":"63","author":"Liu","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"issue":"3","key":"10.1016\/bs.apha.2024.10.008_bib73","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1021\/acs.jmedchem.1c01851","article-title":"Discovery, X-ray crystallography, and anti-inflammatory activity of bromodomain-containing protein 4 (BRD4) BD1 inhibitors targeting a distinct new binding site","volume":"65","author":"Liu","year":"2022","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.apha.2024.10.008_bib74","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ejmech.2018.04.006","article-title":"Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation","volume":"151","author":"Liu","year":"2018","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"3","key":"10.1016\/bs.apha.2024.10.008_bib75","first-page":"S11","article-title":"Novel BRD4 inhibitors block the pathological activation of BRD4-NFKB signaling and suppress colonic inflammation in IBD mouse models","volume":"158","author":"Liu","year":"2020","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/bs.apha.2024.10.008_bib76","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1021\/acs.jmedchem.6b01761","article-title":"Drug discovery targeting bromodomain-containing protein 4","volume":"60","author":"Liu","year":"2017","journal-title":"Journal of Medicinal Chemistry"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.008_bib77","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","article-title":"Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4","volume":"22","author":"Lu","year":"2015","journal-title":"Chemistry & Biology"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.008_bib78","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/MEG.0000000000001730","article-title":"Small molecule drugs in the treatment of inflammatory bowel diseases: Which one, when and why?\u2014A systematic review","volume":"32","author":"Lucaciu","year":"2020","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"11","key":"10.1016\/bs.apha.2024.10.008_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103774","article-title":"RIPTACs: A groundbreaking approach to drug discovery","volume":"28","author":"Ma","year":"2023","journal-title":"Drug Discovery Today"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.008_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14728222.2023.2175317","article-title":"Bromodomain-containing protein 4 (BRD4): A key player in inflammatory bowel disease and potential to inspire epigenetic therapeutics","volume":"27","author":"Ma","year":"2023","journal-title":"Expert Opinion on Therapeutic Targets"},{"key":"10.1016\/bs.apha.2024.10.008_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113247","article-title":"Specific non-genetic IAP-based protein erasers (SNIPERs) as a potential therapeutic strategy","volume":"216","author":"Ma","year":"2021","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"10","key":"10.1016\/bs.apha.2024.10.008_bib82","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/13543776.2024.2400166","article-title":"An updated patent review of BRD4 degraders.","volume":"34","author":"Ma","year":"2024","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/bs.apha.2024.10.008_bib83","article-title":"Bromodomain-containing protein 4 regulates innate inflammation in airway epithelial cells via modulation of alternative splicing","author":"Mann","year":"2023","journal-title":"bioRxiv"},{"issue":"4","key":"10.1016\/bs.apha.2024.10.008_bib84","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.rxeng.2019.03.006","article-title":"Acute abdominal pain in patients with Crohn\u2019s disease: What urgent imaging tests should be done?","volume":"61","author":"Marazuela Garcia","year":"2019","journal-title":"Radiologia (Engl Ed)"},{"issue":"818","key":"10.1016\/bs.apha.2024.10.008_bib85","doi-asserted-by":"crossref","first-page":"eadh1641","DOI":"10.1126\/scisignal.adh1641","article-title":"The NF-kappaB signaling system in the immunopathogenesis of inflammatory bowel disease","volume":"17","author":"Mukherjee","year":"2024","journal-title":"Science Signaling"},{"issue":"4","key":"10.1016\/bs.apha.2024.10.008_bib86","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/d41573-023-00044-6","article-title":"Proximity-inducing drugs get closer","volume":"22","author":"Mullard","year":"2023","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.008_bib87","doi-asserted-by":"crossref","first-page":"604","DOI":"10.5009\/gnl19019","article-title":"Perspectives on current and novel treatments for inflammatory bowel disease","volume":"13","author":"Na","year":"2019","journal-title":"Gut Liver"},{"issue":"10","key":"10.1016\/bs.apha.2024.10.008_bib88","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1517\/13543784.2015.1083010","article-title":"An evaluation of RVX-208 for the treatment of atherosclerosis","volume":"24","author":"Nikolic","year":"2015","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"8","key":"10.1016\/bs.apha.2024.10.008_bib89","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1172\/JCI120633","article-title":"Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV","volume":"129","author":"Niu","year":"2019","journal-title":"The Journal of Clinical Investigation"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.008_bib90","first-page":"CD013747","article-title":"Certolizumab pegol for maintenance of medically induced remission in Crohn\u2019s disease","volume":"6","author":"Okabayashi","year":"2022","journal-title":"Cochrane Database of Systematic Reviews (Online)"},{"key":"10.1016\/bs.apha.2024.10.008_bib91","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1146\/annurev-med-111717-122956","article-title":"Clinical application and potential of fecal microbiota transplantation","volume":"70","author":"Ooijevaar","year":"2019","journal-title":"Annual Review of Medicine"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.008_bib92","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12038-016-9600-6","article-title":"Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases","volume":"41","author":"Padmanabhan","year":"2016","journal-title":"Journal of Biosciences"},{"issue":"9","key":"10.1016\/bs.apha.2024.10.008_bib93","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40265-021-01528-8","article-title":"Targeting sphingosine-1-phosphate signaling in immune-mediated diseases: Beyond multiple sclerosis","volume":"81","author":"Perez-Jeldres","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/bs.apha.2024.10.008_bib94","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cbpa.2020.02.003","article-title":"Domain-selective targeting of BET proteins in cancer and immunological diseases","volume":"57","author":"Petretich","year":"2020","journal-title":"Current Opinion in Chemical Biology"},{"key":"10.1016\/bs.apha.2024.10.008_bib95","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211059954","article-title":"Tumour necrosis factor inhibitors in inflammatory bowel disease: The story continues","volume":"14","author":"Peyrin-Biroulet","year":"2021","journal-title":"Therapeutic Advances in Gastroenterology"},{"issue":"15","key":"10.1016\/bs.apha.2024.10.008_bib96","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.1021\/acs.jmedchem.8b00506","article-title":"Discovery of QCA570 as an exceptionally potent and efficacious proteolysis targeting chimera (PROTAC) degrader of the bromodomain and extra-terminal (BET) proteins capable of inducing complete and durable tumor regression","volume":"61","author":"Qin","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.apha.2024.10.008_bib97","article-title":"Crohn disease","author":"Ranasinghe","year":"2024","journal-title":"In StatPearls"},{"key":"10.1016\/bs.apha.2024.10.008_bib98","doi-asserted-by":"crossref","DOI":"10.1177\/1756284819853208","article-title":"New biologics and small molecules in inflammatory bowel disease: An update","volume":"12","author":"Sabino","year":"2019","journal-title":"Therapeutic Advances in Gastroenterology"},{"issue":"4","key":"10.1016\/bs.apha.2024.10.008_bib99","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ajg.2020.08.003","article-title":"Faecal calprotectin levels after rifaximin treatment in patients with irritable bowel syndrome with diarrhoea: A single-center prospective study","volume":"21","author":"Safwat","year":"2020","journal-title":"Arab Journal of Gastroenterology"},{"issue":"15","key":"10.1016\/bs.apha.2024.10.008_bib100","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"13","key":"10.1016\/bs.apha.2024.10.008_bib101","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"Supplement_1","key":"10.1016\/bs.apha.2024.10.008_bib102","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/ibd\/izac247.009","article-title":"Development of nanoparticle-encapsulated BRD4 inhibitors for novel epigenetic therapeutics of IBD","volume":"29","author":"Shah","year":"2023","journal-title":"Inflammatory Bowel Diseases"},{"issue":"4","key":"10.1016\/bs.apha.2024.10.008_bib103","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1053\/j.gastro.2023.03.019","article-title":"Development of nanoparticle-encapsulated BRD4 inhibitors for novel epigenetic therapeutics of IBD","volume":"164","author":"Shah","year":"2023","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.008_bib104","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1021\/acschembio.2c00747","article-title":"CRISPR screen reveals BRD2\/4 molecular glue-like degrader via recruitment of DCAF16","volume":"18","author":"Shergalis","year":"2023","journal-title":"ACS Chemical Biology"},{"issue":"9","key":"10.1016\/bs.apha.2024.10.008_bib105","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","article-title":"Achieving clinical success with BET inhibitors as anti-cancer agents","volume":"124","author":"Shorstova","year":"2021","journal-title":"British Journal of Cancer"},{"key":"10.1016\/bs.apha.2024.10.008_bib106","doi-asserted-by":"crossref","DOI":"10.1093\/crocol\/otaa067","article-title":"Clinical predictors of response to faecal microbiota transplantation in patients with active ulcerative colitis","author":"Sood","year":"2020","journal-title":"Journal of Crohn\u2019s and Colitis"},{"issue":"5","key":"10.1016\/bs.apha.2024.10.008_bib107","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1021\/acs.jmedchem.0c01487","article-title":"Targeting bromodomain and extraterminal proteins for drug discovery: From current progress to technological development","volume":"64","author":"Tang","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.008_bib108","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1165\/rcmb.2017-0445OC","article-title":"Efficacy of novel highly specific bromodomain-containing protein 4 inhibitors in innate inflammation-driven airway remodeling","volume":"60","author":"Tian","year":"2019","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"issue":"4","key":"10.1016\/bs.apha.2024.10.008_bib109","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.celrep.2018.03.106","article-title":"Selective antagonists of the bronchiolar epithelial NF-kappaB-bromodomain-containing protein 4 pathway in viral-induced airway inflammation","volume":"23","author":"Tian","year":"2018","journal-title":"Cell Reports"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.008_bib110","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/anie.201507978","article-title":"Small-molecule PROTACS: New approaches to protein degradation","volume":"55","author":"Toure","year":"2016","journal-title":"Angewandte Chemie (International Ed. in English)"},{"issue":"8","key":"10.1016\/bs.apha.2024.10.008_bib111","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1016\/j.celrep.2019.10.066","article-title":"The bromodomain protein 4 contributes to the regulation of alternative splicing","volume":"29","author":"Uppal","year":"2019","journal-title":"Cell Reports"},{"issue":"8","key":"10.1016\/bs.apha.2024.10.008_bib112","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41575-022-00604-y","article-title":"Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?","volume":"19","author":"Villablanca","year":"2022","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"issue":"5","key":"10.1016\/bs.apha.2024.10.008_bib113","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/ibd\/izac246","article-title":"The clinical response of upadacitinib and risankizumab is associated with reduced inflammatory bowel disease anti-TNF-alpha inadequate response mechanisms","volume":"29","author":"Wang","year":"2023","journal-title":"Inflammatory Bowel Diseases"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.008_bib114","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41392-020-00384-4","article-title":"The BET family in immunity and disease","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"16","key":"10.1016\/bs.apha.2024.10.008_bib115","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.2174\/1568026618666181010101922","article-title":"Proteolysis targeting chimera (PROTAC): A paradigm-shifting approach in small molecule drug discovery","volume":"18","author":"Wang","year":"2018","journal-title":"Current Topics in Medicinal Chemistry"},{"issue":"15","key":"10.1016\/bs.apha.2024.10.008_bib116","doi-asserted-by":"crossref","first-page":"10824","DOI":"10.1021\/acs.jmedchem.3c01028","article-title":"Discovery of a bromodomain and extra terminal domain (BET) inhibitor with the selectivity for the second bromodomain (BD2) and the capacity for the treatment of inflammatory diseases","volume":"66","author":"Wang","year":"2023","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.008_bib117","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13148-020-00943-0","article-title":"BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes","volume":"12","author":"Wasiak","year":"2020","journal-title":"Clinical Epigenetics"},{"issue":"6241","key":"10.1016\/bs.apha.2024.10.008_bib118","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science (New York, N.Y.)"},{"issue":"18","key":"10.1016\/bs.apha.2024.10.008_bib119","doi-asserted-by":"crossref","first-page":"13141","DOI":"10.1074\/jbc.R700001200","article-title":"The double bromodomain-containing chromatin adaptor BRD4 and transcriptional regulation","volume":"282","author":"Wu","year":"2007","journal-title":"The Journal of Biological Chemistry"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.008_bib120","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.molcel.2023.11.022","article-title":"IDR-targeting compounds suppress HPV genome replication via disruption of phospho-BRD4 association with DNA damage response factors","volume":"84","author":"Wu","year":"2024","journal-title":"Molecular Cell"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.008_bib121","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.molcel.2020.04.034","article-title":"Opposing functions of BRD4 isoforms in breast cancer","volume":"78","author":"Wu","year":"2020","journal-title":"Molecular Cell"},{"issue":"11","key":"10.1016\/bs.apha.2024.10.008_bib122","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.tcb.2014.09.005","article-title":"BRD4 is on the move during inflammation","volume":"24","author":"Xu","year":"2014","journal-title":"Trends in Cell Biology"},{"key":"10.1016\/bs.apha.2024.10.008_bib123","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/17460441.2023.2187777","article-title":"Novel approaches to targeted protein degradation technologies in drug discovery","volume":"18","author":"Xue","year":"2023","journal-title":"Expert Opinion on Drug Discovery"},{"issue":"8","key":"10.1016\/bs.apha.2024.10.008_bib124","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acschembio.5b00216","article-title":"Selective small molecule induced degradation of the BET bromodomain protein BRD4","volume":"10","author":"Zengerle","year":"2015","journal-title":"ACS Chemical Biology"},{"issue":"4","key":"10.1016\/bs.apha.2024.10.008_bib125","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/mco2.104","article-title":"NF-kappaB signaling in inflammation and cancer","volume":"2","author":"Zhang","year":"2021","journal-title":"MedComm (2020)"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.008_bib126","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1021\/acs.jmedchem.6b01816","article-title":"Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression","volume":"61","author":"Zhou","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.apha.2024.10.008_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.117033","article-title":"A comprehensive review of BET-targeting PROTACs for cancer therapy","volume":"73","author":"Zhou","year":"2022","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/bs.apha.2024.10.008_bib128","article-title":"BRD4 blockage alleviates pathological cardiac hypertrophy through the suppression of fibrosis and inflammation via reducing ROS generation","volume":"121","author":"Zhu","year":"2020","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie"}],"container-title":["Advances in Pharmacology","Emerging Therapeutic Targets and Drug Delivery Approaches in IBD"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358924000371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358924000371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:27:26Z","timestamp":1762360046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1054358924000371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443313585"],"references-count":128,"URL":"https:\/\/doi.org\/10.1016\/bs.apha.2024.10.008","relation":{},"ISSN":["1054-3589"],"issn-type":[{"value":"1054-3589","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}